Athens Research/Cambio - Excellence in Molecular Biology/25,000 Units enzyme only/ERT12925K-ENZ

价格
面议
货号:ERT12925K-ENZ
浏览量:127
品牌:Athens Research
服务
全国联保
正品保证
正规发票
签订合同
商品描述
PCR

PCR : PCR Products

The FailSafe™ PCR system for templates up to 20kb long, high GC content (up to 85% G+C), & Multiplex PCR

  • Catalogue
  • Description
  • Protocols
  • Notes
  • Applications & Benefits

EpiScript™ RNase H- Reverse Transcriptase

EpiScript™ RNase H- Reverse Transcriptase, an alternative to Superscript® II, is a recombinant MMLV reverse transcriptase with reduced RNase H activity. It is highly efficient at producing full-length cDNA from long RNA templates. EpiScript RT demonstrates significantly more activity than other MMLV reverse transcriptase enzymes.

BioSearch Tech (Lucigen/Epicentre)

Catalogue No.DescriptionPack SizePriceQty
  • Change to:
  • €
ERT12910KEpiScript™ RNase H- Reverse Transcriptase10,000 Units£104.00QuantityAdd to Order
ERT12925KEpiScript™ RNase H- Reverse Transcriptase25,000 Units£161.00QuantityAdd to Order
ERT12925K-1.25MLEpiScript™ RNase H- Reverse Transcriptase250,000 Units£741.00QuantityAdd to Order
ERT12925K-ENZEpiScript™ RNase H- Reverse Transcriptase25,000 Units enzyme only£88.00QuantityAdd to Order

EpiScript™ RNase H- Reverse Transcriptase

EpiScript™ RNase H- Reverse Transcriptase, an alternative to Superscript® II, is a recombinant MMLV reverse transcriptase with reduced RNase H activity. It is highly efficient at producing full-length cDNA from long RNA templates. EpiScript RT demonstrates significantly more activity than other MMLV reverse transcriptase enzymes.

BioSearch Tech (Lucigen/Epicentre)

ApplicationsFirst-strand cDNA synthesis for subsequent PCR or real-time PCR.

EpiScript™ Rnase H- Reverse Transcriptase (EpiScript RT), an alternative to SuperScript® II Reverse Transcriptase, is a recombinant MMLV reverse transcriptase with greatly reduced RNase H activity. It is highly efficient at producing full-length cDNA from long RNA templates. EpiScript RT is capable of producing cDNA from as little as 50 pg of total RNA for real-time RT-PCR (qRT-PCR) analysis and other applications.The enzyme is available in 25,000 and 50,000 unit sizes at a concentration of 200 U/µl. The enzyme is supplied with a 10X Reaction buffer and 100 mM DTT.

Storage: Store only at -20°C in a freezer without a defrost cycle.

Storage Buffer: EpiScript RT is supplied in a 50% glycerol solution containing 50 mM Tris-HCl (pH 7.5), 100 mM sodium chloride, 1 mM DTT, 0.1 mM EDTA, and 0.1% Triton® X-100.

Unit Definition: One unit of EpiScript RT catalyzes the incorporation of 1 nmol of dTTP into acid-insoluble material in 10 minutes at 37°C using saturating amounts of oligo(dT)-primed poly(rA) as template.

Contaminating Activity Assays: EpiScript RT is free of detectable exonuclease, endonuclease, and RNase activities.

Figure 1

Figure 1. EpiScript™ Reverse Transcriptase performed equally or better than comparable reverse transcriptases from other vendors in 2nd strand-qPCR reactions. First- strand synthesis reactions were assembled according to manufacturer´s specifications. Input RNA was 1 µg of Jurkat total RNA (Ambion®). Reactions were primed using 50 ng of poly-T(16-18) DNA. 2nd strand qPCR was performed using Bio-Rad iQ SYBR mastermix and gene-specific primers that yielded 250-350 bp amplicons. Reactions were repeated 4-fold. PGDF-R (Platelet Derived Growth Factor Receptor), TNF (Tumor Necrosis Factor), IL-1b (Interleukin-1 beta), IL-2 (Interleukin 2). Image courtesy of Matthew Kellinger, Illumina® Inc.

Figure 2AFigure 2BFigure 2 (click to enlarge). EpiScript™ Reverse Transcriptase produces similiar transcript coverage independent of transcript length. EpiScript was used to prime first strand cDNA either from total RNA using oligo-dT (top panel) or polyAselected RNA with random hexamers (bottom panel). The cDNA was converted into Illumina®-compatible libraries and sequenced. The reads were aligned to transcripts based upon various length classes and read density plotted relative to the percent distance from the 5´ end of the transcripts; 0% refers to the 5´ end and 100 % is the 3´ end. As expected, oligo-dT priming results in a more pronounced 3´ bias than random priming.

Figure 3Figure 3. Use of EpiScript® Reverse Transcriptase for first strand cDNA results in detection of similar transcript categories independent of input amount. EpiScript RT was used to random prime 5 ng or 50 pg of human total RNA and the cDNA was converted into libraries for Illumina® sequencing. Reads were aligned using Tophat and annotated with Cufflinks and the percentage of each major category is visualized as a pie chart. Equivalent results are observed for both 5 ng and 50 pg of input RNA.

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

EpiScript™ RNase H- Reverse Transcriptase

EpiScript™ RNase H- Reverse Transcriptase, an alternative to Superscript® II, is a recombinant MMLV reverse transcriptase with reduced RNase H activity. It is highly efficient at producing full-length cDNA from long RNA templates. EpiScript RT demonstrates significantly more activity than other MMLV reverse transcriptase enzymes.

BioSearch Tech (Lucigen/Epicentre)

Latest protocol is available here

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

EpiScript™ RNase H- Reverse Transcriptase

EpiScript™ RNase H- Reverse Transcriptase, an alternative to Superscript® II, is a recombinant MMLV reverse transcriptase with reduced RNase H activity. It is highly efficient at producing full-length cDNA from long RNA templates. EpiScript RT demonstrates significantly more activity than other MMLV reverse transcriptase enzymes.

BioSearch Tech (Lucigen/Epicentre)

Concentration: 200 U/μlSupplied with: 10X Reaction Buffer, 100 mM DTTShipping medium: blue iceStorage temp: -20°C

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

EpiScript™ RNase H- Reverse Transcriptase

EpiScript™ RNase H- Reverse Transcriptase, an alternative to Superscript® II, is a recombinant MMLV reverse transcriptase with reduced RNase H activity. It is highly efficient at producing full-length cDNA from long RNA templates. EpiScript RT demonstrates significantly more activity than other MMLV reverse transcriptase enzymes.

BioSearch Tech (Lucigen/Epicentre)

First-strand cDNA synthesis for subsequent PCR or real-time PCR.

Concentration: 200 U/μlSupplied with: 10X Reaction Buffer, 100 mM DTTShipping medium: blue iceStorage temp: -20°C

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

Myeloperoxidase Enzyme Immunoassay Kit 髓过氧化物酶 免疫分析试剂盒 Human MPO EIA KIT FEATURES: USE - Measure human MPO in a variety of matrices SAMPLE -Serum, Platelet-Poor Heparin Plasma, Saliva, Urine or Tissue Culture Media SAMPLES / KIT - 40 in duplicate SENSITIVITY - 0.068 ng/mL STABILITY - liquid reagents stable at 4°C QUICK RESULTS - 2.5 HOURS Myeloperoxidase (MPO) is a tetrameric heme-containing protein abundantly produced in neutrophil granulocytes where it plays an important anti-microbial role. During degranulation MPO is released into the extracellular space. There, as part of the neutrophils “respiratory burst”, it produces hypochlorous acid from hydrogen peroxide and Cl–. MPO also uses hydrogen peroxide to oxidize tyrosine to the tyrosyl radical. Both hypochlorous acid and tyrosyl are cytotoxic and when present can kill bacteria and other pathogens. Hereditary deficiency of myeloperoxidase predisposes individuals to immune deficiency. Studies have shown an association between elevated MPO levels and coronary artery disease, and in 2003 it was suggested that MPO may serve as a sensitive predictor of myocardial infarction in patients complaining of chest pain. Since that time the clinical utility of MPO testing in cardiac patients has been solidly established in the literature with well over 100 papers published. In 2010 this clinical application was further refined by additional studies which determined that measuring both MPO and C-reactive protein (CRP) provided more accurate prediction of mortality risk than measuring just CRP alone.